Cystic Fibrosis Treatment Report
www.CysticFibrosisTreatmentReport.com
https://clinicaltrials.gov/ct2/show/NCT04043806
https://clinicaltrials.gov/ct2/show/NCT04043806?recrs=abdf&type=Intr&cond=Cystic+Fibrosis&lupd_s=07%2F19%2F2019&lupd_d=14
Condition : Cystic Fibrosis
Interventions : Drug: ELX/TEZ/IVA; Drug: IVA
Sponsor : Vertex Pharmaceuticals Incorporated
Not yet recruiting
A Study Evaluating the Long-term Safety of VX-445 Combination Therapy
NCT04043806
Fri, 02 Aug 2019 12:00:00 EDT
Last Update Posted: 08/02/19 07:07AM
https://investors.vrtx.com/news-releases/news-release-details/vertex-selects-triple-combination-regimen-vx-445-tezacaftor-and
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000184-89
EudraCT Number: 2018-000184-89
Sponsor Protocol Number: VX17-445-103
Sponsor Name: Vertex Pharmaceuticals Incorporated
Start Date: 2018-09-07
Medical condition:
Disease:
Version: 20.0
SOC Term: 10010331 – Congenital, familial and genetic disorders
Classification Code: 10011762
Term: Cystic fibrosis
Level: PT
Population Age: Adolescents, Under 18, Adults
Gender: Male, Female
Trial Protocol: BE (Completed), NL (Ongoing)
A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del Mutation (…
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000184-89
Last Update Posted: 05/01/19 05:56AM
https://clinicaltrials.gov/ct2/show/NCT03525574?recrs=abdf&type=Intr&cond=Cystic+Fibrosis&lupd_s=02%2F04%2F2019&lupd_d=14
Condition : Cystic Fibrosis
Interventions : Drug: VX-445; Drug: TEZ; Drug: IVA
Sponsor : Vertex Pharmaceuticals Incorporated
Enrolling by invitation
A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
NCT03525574
Tue, 15 May 2018 12:00:00 EDT
Last Update Posted: 02/18/19 10:26AM
